Mauro D’Amico

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology · 2015 · 1.1K citations · Full text

Phase 3, Gastrointestinal Oncology, Medicine +8

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Chiara Cremolini, Fotios Loupakis, C. Antoniotti et al. · Annals of Oncology · 2015 · 191 citations · Full text

Early Tumor Shrinkage, Medicine, Colorectal Cancer +6

Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment

Tania Buttiron Webber, Nicoletta Provinciali, Marco Musso et al. · European Journal of Cancer · 2021 · 46 citations · Full text

Vaccination, Vaccine Safety, Poor Seroconversion +8

Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET

Alessandra Gennari, Étienne Brain, A. De Censi et al. · Annals of Oncology · 2024 · 23 citations · Full text

Breast Oncology, Health Sciences, Medicine +10

Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer

Davide Serrano, Sara Gandini, Parjhitham Thomas et al. · JAMA Oncology · 2023 · 20 citations · Full text